key: cord-0921988-kyoa5gsf
authors: Butler, Daniel J.; Mozsary, Christopher; Meydan, Cem; Danko, David; Foox, Jonathan; Rosiene, Joel; Shaiber, Alon; Afshinnekoo, Ebrahim; MacKay, Matthew; Sedlazeck, Fritz J.; Ivanov, Nikolay A.; Sierra, Maria; Pohle, Diana; Zietz, Michael; Gisladottir, Undina; Ramlall, Vijendra; Westover, Craig D.; Ryon, Krista; Young, Benjamin; Bhattacharya, Chandrima; Ruggiero, Phyllis; Langhorst, Bradley W.; Tanner, Nathan; Gawrys, Justyna; Meleshko, Dmitry; Xu, Dong; Steel, Peter A. D.; Shemesh, Amos J.; Xiang, Jenny; Thierry-Mieg, Jean; Thierry-Mieg, Danielle; Schwartz, Robert E.; Iftner, Angelika; Bezdan, Daniela; Sipley, John; Cong, Lin; Craney, Arryn; Velu, Priya; Melnick, Ari M.; Hajirasouliha, Iman; Horner, Stacy M.; Iftner, Thomas; Salvatore, Mirella; Loda, Massimo; Westblade, Lars F.; Cushing, Melissa; Levy, Shawn; Wu, Shixiu; Tatonetti, Nicholas; Imielinski, Marcin; Rennert, Hanna; Mason, Christopher E.
title: Shotgun Transcriptome and Isothermal Profiling of SARS-CoV-2 Infection Reveals Unique Host Responses, Viral Diversification, and Drug Interactions
date: 2020-05-01
journal: bioRxiv
DOI: 10.1101/2020.04.20.048066
sha: 0f21544beb39b29181bbf366393f8d071c7e2f2f
doc_id: 921988
cord_uid: kyoa5gsf

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused thousands of deaths worldwide, including >18,000 in New York City (NYC) alone. The sudden emergence of this pandemic has highlighted a pressing clinical need for rapid, scalable diagnostics that can detect infection, interrogate strain evolution, and identify novel patient biomarkers. To address these challenges, we designed a fast (30-minute) colorimetric test (LAMP) for SARS-CoV-2 infection from naso/oropharyngeal swabs, plus a large-scale shotgun metatranscriptomics platform (total-RNA-seq) for host, bacterial, and viral profiling. We applied both technologies across 857 SARS-CoV-2 clinical specimens and 86 NYC subway samples, providing a broad molecular portrait of the COVID-19 NYC outbreak. Our results define new features of SARS-CoV-2 evolution, nominate a novel, NYC-enriched viral subclade, reveal specific host responses in interferon, ACE, hematological, and olfaction pathways, and examine risks associated with use of ACE inhibitors and angiotensin receptor blockers. Together, these findings have immediate applications to SARS-CoV-2 diagnostics, public health, and new therapeutic targets.

In March 2020, the World Health Organization (WHO) declared a pandemic of the coronavirus 76 disease 2019 (COVID-19), an infection caused by severe acute respiratory syndrome coronavirus 77 2 (SARS-CoV-2) (He et al., 2020) . Since its start, more than three million of cases and more 78 than two hundred of thousand deaths have been reported (https://coronavirus.jhu.edu), with an 79 especially high burden in New York City (NYC). Since the presenting symptoms of COVID-19 80

can resemble those of common viral respiratory infections, a molecular diagnosis is required to 81

reliably distinguish a SARS-CoV-2 infection from influenza and other respiratory illnesses 82 (Guan et al., 2020 , Zhou et al., 2020 . 83 84

The current gold standard (qRT-PCR-based) approaches to SARS-CoV-2 molecular testing are 85 largely limited to hospital or academic laboratories and reserved for the most severe cases, with 86 limited accessibility to the general public. As a result, the true prevalence of SARS-CoV-2 in the 87 population is mostly unknown, particularly among pre-symptomatic, mild symptomatic, or 88 asymptomatic cases. Though several novel, scalable biotechnological approaches for viral testing 89 have recently emerged (e.g., CRISPR-Cas12a (Broughton et al., 2020) Related pathogens, high prevalence disease agents, and normal or pathogenic microbiota that are 139 reasonably likely to be encountered in the clinical samples were evaluated to identify the percent 140 homology between the primer sequences and these other organisms, and the probes were also 141 designed to avoid known polymorphisms (see Methods). 142 143 To validate the assay, we first evaluated two synthetic RNAs (see Methods) whose sequences 144 matched the viral sequences of patients from Wuhan, China and Melbourne, Australia (Supp. 145 Fig. 1 ). The first control (MT007544.1) was used to test the analytical sensitivity via the limit of 146 detection (LoD), titrated from 1 million molecules of virus (10 6 ) down to a single copy, using 147 serial log10 dilutions. The reaction output was measured at 0-, 20-, and 30-minute intervals 148 (Figure 1c, Supp. Figure 2a) before the samples were heated to 95 o C for inactivation. LAMP 149 fluorescence correlated closely with SARS-CoV-2 RNA viral copies (Figure 1d) , with an 150 overlap of the median signal from negative controls at lower levels (0-10 total copies per 151 reaction) of viral RNA (n=10). The LoD was found to be between 5-25 viral total copies for the 152 dual primer, single-tube reaction (N gene and E gene), and this was then replicated to show a 153 similar LoD on the second synthetic control from a patient from Wuhan (Supp. Figure 2b, 3a) . 154 155

To optimize the LAMP assay for clinical samples, we first tested the reaction on a range of 156 sample types, dilutions, and reaction volumes. We used a set of 201 samples from known or 157

suspected COVID-19 cases that were tested for SARS-CoV-2 by a commercial qRT-PCR assay 158 that has been the primary clinical test at NYPH-WCMC since early March. These comprised 69 159 nasopharyngeal (NP) swab samples that tested positive (qRT-PCR positives, Ct<40) and 132 160 samples that tested negative (qRT-PCR negative, Ct ≥ 40) (see Methods). qRT-PCR positive 161 samples showed a much higher LAMP fluorescence than qRT-PCR negative samples, with 162

superior performance observed at higher (10µL vs 5µL) input volumes (Supp. Figure 3b) . PCR positive samples that failed to generate LAMP fluorescence were associated with lower 164 viral genome abundance (high cycle threshold [Ct] value qRT-PCR). We obtained similar 165 performance on bulk oropharyngeal swab lysate (Supp. Analysis of Receiver Operator Characteristic (ROC) curves revealed an optimal threshold of 172 11,140 QuantiFluor relative fluorescence units (RFUs), which yielded an overall sensitivity of 173 95.6% and specificity of 99.2% (Figure 1e) . We observed higher LAMP sensitivity at higher 174 viral loads, as determined by qRT-PCR Ct values (Supp. Fig. 4) . The highest viral load (Ct <20) 175 showed 100.0% sensitivity and 97.4% specificity, compared with the sensitivity at the lowest 176 viral load at 80.0% (Ct >28, RFU below 7010). These same LAMP assay thresholds yielded 177 consistent test positivity for synthetic RNA positive controls (Twist Biosciences) as well as 178 clinical spike-in carrier RNAs (20/20) (Supp. Fig. 4) , and consistent signal from clinical viral 179 positives in Vero E6 cells (100.0%, 12/12) and blank clinical buffer negatives (100.0% 8/8). 180 181

Shotgun metatranscriptomics platform for viral, microbiome, and host genomics 182 To provide orthogonal validation of our LAMP assay and further investigate the biological 183 characteristics of qRT-PCR positive and negative specimens, we developed a shotgun 184 metatranscriptomics platform utilizing total RNA-seq (RNA-sequencing with ribosomal RNA 185 depletion) to profile all RNAs from patient and environmental swab specimens (Figure 1a) . We 186 sequenced 857 RNA-seq libraries (Figure 2) Figure  202 5a), as well as RNA-seq extraction replicates (Supp. Figure 5b) . These results provide 203 additional validation for the LAMP SARS-CoV-2 assay on clinical samples. 204 205

Analysis of total RNA-seq sequences also enabled mapping of likely co-infections and 206 colonization with commensal species across both clinical positives and negatives in our sample 207 set. We identified additional RNA viruses and organisms that distinguished high, medium, and 208 lower viral load patients (Supp Table 1 , Supp. Figure 6) , with overall similarity observed 209 across patients in the bacterial RNA fractions (Supp. Figure 7a) . Table 1 ). However, we did not observe 230 significant counts or proportions (Figure 3a ) of SARS-CoV-2 reads, which was particularly 231

clear with dual-index library preparations (Supp. Figure 8) . However, a broad range of other 232 bacterial and viral species was found, including a large set of phages (e.g. Streptomyces phage 233 VWB), desiccation-tolerant bacteria (e.g Deinococcus radiodurans), and more abundant 234 bacterial and archaeal RNA than the clinical samples (Supp . Table 1) . Of note, these were 235 checked against a database of putative false positives (Supp . Table 2) , which was created from 236

in silico fragmentation of the SARS-CoV-2 genome and mapping against the same database. 237

Taken together, these results indicate that high transit surfaces were not likely to harbor 238 significant levels of SARS-CoV-2 in the early phases of the NYC epidemic. 239 240 SARS-CoV-2 assemblies from shotgun metatranscriptomes 241

The abundance of SARS-CoV-2 alignments from total RNA-seq was sufficient to provide >10x 242 coverage of the viral genomes and yield high quality, full-length assemblies for 155 samples, 243

including 146 (67.6%) of qRT-PCR positive patient samples (Figure 3a, Supp. Figure 6) . The 244 97 qRT-PCR positive samples that yielded partial or no assembly demonstrated low or uneven 245 genome-wide read depth, though these were increased on average relative to qRT-PCR 246 negatives. We also generated full length SARS-CoV-2 assemblies for 9 samples that were found 247 negative by qRT-PCR (Figure 3a) . Each of these demonstrated a high RPKM viral load, an 248 abundance of reads evenly covering the SARS-CoV-2 genome, and high (>0.5) variant allele 249 fractions (VAFs) of SNV's commonly seen in positive samples, as well as a recent build of 250 GISAID (Figure 3b) . Apart from these common variant sites, we did not find additional 251 recurrent mutations that might explain why these cases were not detected by qRT-PCR (e.g. 252 primer site mutation Analysis of VAF posterior probability distributions identified a subset of alleles whose VAFs 259

were confidently (probability > 0.95) above 0.05 but below 0.95. We labeled these alleles as 260

"het" (heterogenous) variants and refer to the remaining (high VAF) consensus assembly variants 261 as "homogeneous." Many of these het variants were associated with robust read support despite 262 frequently having VAFs below 0.5 and not being incorporated into the consensus assembly 263 sequence. A subset of samples (11/155) samples harbored at least 5 het variants, with a 264 significant enrichment (P = 0.0054) in qRT-PCR negative cases (Figure 3c) . Analyzing the 265 population allele frequencies (PAF) of these het variants across GISAID revealed the vast 266 majority (91%) to be rare (PAF<0.1) or even private to that sample, indicating that these were 267 unlikely to be due to cross contamination (Figure 3d ). 268 269

We then asked whether het variants might indicate the presence of a viral subclone, arising either 270 through co-infection or intra-host adaptation. Analyzing het-rich (>5 het variants) samples, 271 revealed that set of het variants observed in a single sample showed similar VAFs, yielding clear 272 peaks when summing their individual posterior probability densities (Figure 3e) . These results 273

were consistent with the presence of a viral subclone at some fraction f corresponding to the 274 modes of each of these VAF distributions (0.1-0.2). Interestingly, each of the three samples 275

shown in Figure 3e also harbored a clear peak of homogenous variants with VAFs near 1. These 276 results suggest that the viral subclone is not the result of a coinfection by two viruses, which 277 would yield a second peak at 1-f at every major clone variant that has the reference allele in the 278 minor subclone. Het variants were found to occur at common sites of consensus variants across 279 samples, however, rare private hets were also present (Figure 3f ).

Global phylogenetic relationship of NYC strains 282 We next integrated 141 full-length NYPH-WCMC sequences with 7,806 SARS-CoV-2 283 sequences obtained from a recent GISAID build (downloaded on 4/20/2020) into a maximum 284 likelihood phylogenetic tree using the Nextstrain algorithm (Hadfield et the "L" strain, which is defined by a reference base at position 28143 (ORF8) and previously 293 associated with severe cases in Wuhan (Tang et al., 2020) (Figure 4b ).

Among the A2 cases in our cohort, we found a recurrent 9 bp in-frame deletion (g.686_694del) 296

in the gene encoding non-structural protein 1 (NSP1). NSP1 is a putative SARS-CoV-2 virulence 297 factor that is highly divergent across betacoronaviruses (Narayanan et al., 2015) . This deletion 298 was assembled in 3 of 93 NYPH-WCMC samples, in which it showed robust read support with 299 near >0.95 VAF across thousands of high-quality alignments to the locus (Figure 4c ). An 300 identical deletion was observed in 15 other samples in the GISAID database, spanning samples 301 from England, Iceland, and Canada, as well as three additional cases from New York. Among 302 these, 12 of 15 were labeled as part of clade A2 by Nextstrain, while two (Washington state) 303 cases were associated with a distant clade B1 (Figure 4d ). This deletion removes three amino 304 acids (p.141_143KSD), including a residue that is variant (143Y>F) relative to the SARS-CoV-1 305 genome (Figure 4c ). Interestingly, a 16th case (Washington, clade A2, Figure 4c ) showed a 306 related but not identical 9 bp in-frame deletion (g.686_694del) that removes the same three 307 residues. These residues occur in a conserved portion of the C-terminal region of NSP1, which 308 has been linked to host chemokine dysregulation and translational inhibition in SARS-CoV 309 (Narayanan et al., 2015) .

Given the predominance of clade A2 among NYC cases, we next asked whether specific variants 313

were enriched in NYC A2 samples relative to other regions' A2 samples. Comparing variant 314 frequencies between A2 cases in our data and non-NYC cases in GISAID, we identified six 315 enriched loci with FDR<0.1 (Fisher's exact test, one-tailed) that were over-represented in NYC 316 A2 samples (Figure 5a ). All six of these variants were significantly enriched (Bonferroni-317 adjusted p-value <0.05) in a second analysis comparing all other cases from NYC in GISAID vs. 318 the rest of the world (Figure 5a) . Visualizing the most significant of these variants across the 319

Nextstrain derived phylogenetic tree (Figure 5b ) demonstrated that the highest frequency of 320 these variants (25563G>T), defined a novel subclade of A2, which we call A2-25563. This 321 subclade comprised 84.4% (572/678) of (NYPH-WCMC and GISAID) NYC samples, and 322 92.7% (572/617) of the A2 portion of NYC cases (Sinai and NYU). Interestingly, while all three 323 of the NYPH-WCMC A2 cases harboring the aforementioned NSP1 9-bp deletion were in A2-324 25563, many of the remaining cases were distributed across other subclades. Unlike the SNVs 325 used to define A2-25563, this deletion appeared to be highly polyphyletic with 7 unique 326 phylogenetic clusters associated with the deletion across a variety of clades (Figure 4c , Figure  327 5b). 328 329

Investigating the geographical and temporal distribution of non-NYC samples in A2-25563, we 330

found a global distribution with likely origin in Western Europe (Figure 5c, 5d) . The first noted 331 case of A2-25563 in GISAID was in Belgium on 2/21/2020, but since then, this putative 332 subclade has represented a minority (20%) of Western European cases. While the prevalence of 333 A2-25563 in NYC appeared to be consistently high across sampling dates, it constituted only a 334 moderate proportion of cases from the Western and (non-New York portion of the) Eastern USA 335 (<50%) in early March (Figure 5d) . Strikingly, we found that of the prevalence of the A2-25563 336 clade across Eastern and Western United States steadily and significantly increased through late 337

March and early April, while remaining stable in the Midwest. Among the early locations 338

showing high fractions of A2-25563 was West Africa, which has steadily decreased in 339 prevalence since early March (Figure 5d ). The SNVs defining A2-25563 subclade were non-340 synonymous variants targeting genes encoding the non-structural protein 2 (NSP2), the viral 341 replicase, and ORF3a, a poorly characterized SARS-CoV-2 protein with putative roles in 342

inflammation (Siu et al., 2019) . This subclade defining ORF3a site (p.Gln57His) is distinct from 343 that which defines the previously characterized L strain (p.Leu84Ser) (Tang et al., 2020) . 344 345

Defining the SARS-CoV-2 host transcriptome 346 We leveraged the comprehensive nature of the total RNA-seq profiles to better understand the 347 host transcriptome during SARS-CoV-2 infection. Cell proportion analyses using the MUSIC 348 deconvolution algorithm showed enriched proportions of cell types spanning goblet, ciliated 349 airway, and epithelial cells across all samples (Supp. Figure 9 ). Differentially expressed genes 350

(DEGs) associated with SARS-CoV-2 infection were calculated using limma voom and DESeq2 351 (see Methods). Overall, 757 significant DEGs (q<0.01, >1.5-fold change) were found the qRT-352 PCR positive vs. negative samples (Supp . Table 3), spanning 350 up-regulated DEGs and 407  353 down-regulated DEGs, and a total of 8851 unique genes (q<0.01, >1.5-fold change) across 354 different subgroups including a subset that were distinct from other detected viral respiratory 355 infections (Figure 6a , Supp. Figure 12) . These spanned viral response pathways, innate immune 356 response, and interferon signaling (Figure 6b ,d, Supp. Figure 10a ), but also included iron, 357 olfaction, calcium, and ribosome dysregulation. 358 359

Differentially expressed host genes indicated a wide range of antiviral responses, including a 360 common interferon response across all ranges of viral levels, which was significantly higher 361 when compared to SARS-CoV-2 negative samples that harbored other respiratory viruses 362 (Figure 6a,b) . Notably, host cells showed an increase in angiotensin converting enzyme 2 363 (ACE2) expression (Figure 6b ) (p-value=1.4x10 -9 ), which is the SARS-CoV-2 cellular receptor 364 (Hoffmann et al., 2020) . This critical gene for viral entry ( I MHC-mediated antigen processing and  369 Interferon-Stimulated Genes (ISGs) (Figure 6b ,c,d), underscoring the impact of the virus on 370 these cells' immune response (Oudshoorn et al., 2012) . Also, a subset of cytokines (CXCL10, 371 CXCL11, CCL8) showed the highest spike of expression in the higher viral load sub-group 372 (Supp. Figure 10) , matching previous results from animal models and infected cells (Blanco-373 Melo et al., 2020). The host transcriptome that exhibited the greatest amount of DEGs were 374 those with the highest viral titer (Figure 6a ). 375 376

Down-regulated genes and those with a negative enrichment score (NES) were functionally 377 distinct (Figure 6d ). This included a significant decrease in gene expression for the olfactory 378

receptor pathway genes (q-value =0.0005, Supp. indicated a connection to hematological and iron (heme) regulation during infection (Figure 6d ). 385

Accordingly, genes in a related biological network were significantly enriched based on Gene 386

Ontology (GO) pathways for iron regulation (q-value 0.04, Supp. Table 4 ). Both the up-387 regulated and down-regulated gene expression differences in were distinct from those of house-388 keeping genes (Supp. Figure 11) , which stayed mostly stable during infection. 389 390

Finally, given our observation of increased ACE2 gene expression in patients with high SARS-392

CoV-2 viral load, we then investigated the interplay of receiving pharmacologic angiotensin 393 converting enzyme inhibition (ACEI) or angiotensin receptor blockers (ARBs) for hypertension 394

and clinical features of COVID-19 disease. Since ACE2 expression can be increased in patients 395

taking ACEIs and ARBs (Agata et al., 2006) , the observed correlation of viral titer with ACE2 396 expression may be attributed to the pre-infection use of such inhibitors, which is common in 397 older patients and those with comorbidities (Fang et al., 2020) . To address this, we analyzed an 398 observational cohort of 8,856 patients with suspected SARS-CoV-2 infection from New York 399

Presbyterian Hospital-Columbia University Irving Medical Center (NYPH-CUIMC) for their 400 usage of ACEIs and ARBs (4,829 who tested positive). We found that use of ACEIs/ARBs was 401 strongly associated with testing positive in patients suspected of SARS-CoV-2 infection (Odds 402

Ratio, OR=2.7, and 95% Confidence Interval, CI=2.2-3.94, p=7.43E-28, Figure 6e ). This result 403 was consistent when corrected for age, sex, and IL-6 (OR=1. channel blockers (CCBs), another class of anti-hypertensives, and found no association between 407 CCB exposure and infection. We found that patients with hypertension who take ACEIs and 408

ARBs have higher infection rates than patients with hypertension on CCBs (OR=1.5 CI: 1.2-2.0, 409 p=0.0011) ( Table 2) . 410 411 We found a range of effects when investigating the relationship between ACEI/ARB usage and 412 morbidity and mortality. In an uncorrected univariate analysis, ACEI/ARB usage conferred an 413 increased risk of intubation and mortality for SARS-CoV-2 positive patients (intubation: HR=2.8 414 CI:2.3-3.5, 6.99E-24) (Figure 6e and Figure 6f ) and mortality: HR=2.2 CI:1.8-2.7, p=3.18E-14 415 (Figure 6e and Figure 6g ). These results hold when correct for age, sex, and IL6 (Figure 6e) . 416 However, when correcting for comorbidities, only intubation was significant (HR=1. being overweight (p=3.86E-03), and IL-6 (p=8.68E-23). Finally, in a post-hoc comparative 427

analysis between specific ACEIs, we found no significant differences in infection rates, 428

intubation, or mortality with any single ACEI drug over another (Supp. Figure 13) . In a similar 429

analysis on ARBs, we found that olmesartan was associated with an increased risk of mortality 430 (HR=2. The most urgent diagnostic need in this situation is for scalable rapid point-of-care tests that can 444 be potentially implemented in the home. Our validation of a rapid one-tube, dual-primer 445 colorimetric SARS-CoV-2 assay with both qRT-PCR and total RNA-seq provides a potential 446 solution to this problem. Further work will be needed to assess whether this LAMP assay can 447

detect the presence of SARS-CoV-2 at even lower (but clinically relevant) viral concentrations in 448 specimen types that are less cumbersome to collect than naso/oropharyngeal swabs (e.g. saliva, 449 stool). As we demonstrate, this LAMP SARS-CoV-2 assay can be also applied for environmental 450 sampling, which may be crucial in the containment and recovery phases of this pandemic. coronary heart diseases, all which have been associated with increased disease severity (Fang et 506 al., 2020 , Ferrario et al., 2005 . Since these comorbidities are frequently treated with ACE 507 pathway perturbing medications (ACEIs and ARBs), one possibility is that these medications 508 may make patients more susceptible to SARS-CoV-2 infection. 509 510

Though previous epidemiological studies have reported increased mortality and morbidity in 511 COVID-19 patients with hypertension, we sought to examine this risk in the context of ACEI or 512 ARB use (Patel and Verma, 2020) . Our retrospective clinical analysis shows that ACEI/ARB 513 exposure increased COVID-19 risk, but showed equivocal effects for morbidity and mortality 514 when conditioning on hypertension status. A recent study reported a protective effect of 515 ACEI/ARB exposure on mortality . We were able to replicate their result by 516 conditioning on hypertension. However, this same analysis also revealed no effect, or possibly 517 even a risk, from ACEI/ARB exposure on mechanical respiration and a strong risk of infection. 518

Further, the association with infection was consistent regardless of conditioning on hypertension 519

and in a direct comparison to CCB exposure, mitigating some of the concerns about confounding 520 risk. Clinical samples were extracted as described above and then tested with qRT-PCR using primers 615

for the E (envelope) gene, which detects all members of the lineage B of the beta-CoVs, 616

including all SARS, SARS-like, and SARS-related viruses, and a second primer set for the S 617 (spike) gene, which specifically detects the SARS-CoV-2 virus. The reaction also contains an 618 internal control that served as an extraction control and a control for PCR inhibition. 619 620

Samples were annotated using qRT-PCR cycle threshold (Ct) value for SARS-CoV-2 primers. 621

Subjects with Ct less than or equal to 18 were assigned "high viral load" label, Ct between 18 622 and 24 were assigned "medium viral load" and Ct between 24 and 40 were assigned "low viral 623

load" classes, with anything above Ct of 40 was classified as negative. We also predicted a 624 combined viral load score using Ct, GloMax QuantiFluor readout from LAMP experiments and 625 fraction of SARS-CoV-2 matching NGS reads in a sample. For this score (40-Ct), (LAMP 626 readout) and (log10(SARS-CoV-2 fraction + 1e-6)) were all normalized between zero and one 627

individually, and summed together using a combination weight of 5 for Ct, 3 for LAMP and 2 628 for NGS. Table 5 ). Overall, the primers had less than 80% homology with the vast 637 majority of tested pathogen sequences. For any organisms where a primer hit >80% homology, 638 only one of the primers (forward or reverse) had significant homology making an amplified 639 product extremely unlikely. Overall, the results of this analysis predict no significant cross-640 reactivity or microbial interference. We also assessed the potential impact of sequence variation 641 in circulating strains that might lead to poor amplification. In the thousands of sequences 642 deposited in GISAID (Shu and McCauley, 2017) , only one site in the priming region was 643 observed to be polymorphic. The polymorphism (T30359C) was only observed in 106 of 6753 644 (<2%) sequences with coverage of this region. This variant overlaps the priming site of the LB 645 primer but is not near a 3-prime end and is not anticipated to cause amplification failure. The 646 data from Figure 1 show the use of a Bioscience, #MT007544.1) was generated using the lamp assay and in parallel with the qRT-705

PCR. The control RNA was diluted serially 10-fold with water and the absolute copy number, 706

ranging from 10⁵ to 10 -5 was analyzed. Gel electrophoresis after visual read-out of the LAMP 707 assay was done by loading 5 µl of the lamp reaction with 5 µl 2x loading dye on a 1.5 % agarose 708 (Seakem LE Agarose, Lonza #50004) together with 5 µl of a 1kB DNA Ladder (Roche). The 709

electrophoresis was performed at 90 V constant. 710 711

The photometric read-out of the standard curve was performed in a plate reader. To this end the 712 lamp reaction was transferred into a 96-well V-shaped cell-culture plate (Greiner Bio-One, 713 #651180). After measuring the absorbances at 432nm and 560nm, the ratio abs(432)/abs (560) To get an approximation for the positive and negative classification rate, the BBMap random-748 reads script was used to simulate 10 million 150bp paired-end Illumina reads from the database 749 sequences (Segata et al., 2016) . For the negative test all sequences in the database excluding 750 SARS-CoV and SARS-CoV-2 genome were removed from the sequences and the simulated 751 reads were mapped with the Kraken2 database (Supp Table 1 ). 752 753

For the positive test, the same process was repeated using only SARS-CoV-2 genome (Supp. 754 Table 2 ). Positive results show >99% of SARS-CoV-2 reads uniquely map to either SARS-CoV 755

or SARS-CoV-2, with the remaining 1% are ambiguous, potentially matching multiple taxa 756 (Supp. Table 2 ). All sequences were classified using the Kraken2 database. To remove the 757 potential contamination of reads that are homologous across multiple species we used Kraken2 758 outputs to filter sequences to either human (uniquely matching Homo sapiens and no other taxon 759 in our database), SARS-CoV-2 (either matching SARS-CoV or SARS-CoV-2 due to homology 760 between these two viruses), and remaining reads that may be coming from unclassified, archaeal, 761

bacterial, viral, fungal, protozoan or ambiguously mapping reads to human or SARS-CoV (Li, 762 2015). 763 764

Using kraken2 classifications common respiratory pathogens were identified in clinical samples. 765

Any SARS-CoV-2 negative sample with >0.01% relative abundance (normalized after the 766 exclusion of any human, SARS-CoV-2 and uncharacterized reads) for presence of viral 767 pathogens were classified as potential unrelated viral infection (Supp. Figure 7) . These samples 768

were used as controls during specific differential expression comparisons to compare the 769 common effects of viral infections on host cells from SARS-CoV-2 infection. 770 771

Viral Genome Assembly 772

Reads unambiguously mapping to SARS-CoV or SARS-CoV-2 were aligned to the Wuhan-Hu-1 773 (Genbank accession MN908947.3) reference using bwa mem (Li, 2013) . Variants were called 774 using iVar, and pileups and consensus sequences were generated using samtools (Li et al., 2009; 775 Grubaugh . Sequence identity and coverage metrics were calculated using Mview (Brown et 782 al., 1998) . Phylogenetic trees were created using Nextstrain's augur as described above, and 783 visualized using the ggtree package in R (Yu, 2020). 784 785

Viral variant calling and allelic fraction estimation 786

Full-length viral consensus sequences were aligned to the Wuhan-Hu-1 reference using bwa 787 mem (Li, 2013) with default settings. Variants were identified by enumerating the coordinates 788 and query / reference subsequences associated with mismatches (SNV) and gaps in the query 789

(deletion) and reference (insertions) using R/Bioconductor (GenomicRanges, Rsamtools, 790

Biostrings packages) and Imielinski lab gChain packages (https://github.com/mskilab/gChain). 791

Exhaustive variant calling on read alignments was additionally performed using bcftools mpileup Population reference and alternate allele counts were computed for all SNV and indel variant 806 calls detected in at least three cases in the A2 clade subset of our NYPH-WCMC sequences (123 807 cases, see above). Similar counts were computed across 537 New York and 7269 non-New York 808 sequences that were obtained from GISAID and incorporated into the Nextstrain tree (see 809 above). A one-tailed Fisher's Exact test was used to compare allele counts in NYPH-WCMC vs. 810 non-New York GISAID cases. All variants with FDR < 0.1 were reported as significant. 811

Significant variants from the initial analysis were replicated in a similar comparison of New 812

York vs non-New York GISAID sequences. Human Transcriptome Analysis 821

The reads that mapped unambiguously to the human reference genome via Kraken2 were used to 822 detect the host transcriptional response to the virus. Reads matching Homo sapiens were trimmed 823

with TrimGalore, aligned with STAR (v2.6.1d) to the human reference build GRCh38 and the 824 GENCODE v33 transcriptome reference, gene expression was quantified using featureCounts, 825 stringTie and salmon using the nf-core RNAseq pipeline ( 2016; Wang et al., 2012) . Samples that had more than 10 million human mapped reads were 830 used for differential expression analysis. Reads, as reported by featureCounts, were normalized 831 using variance-stabilizing transform (vst) in DESeq2 package in R for visualization purposes in 832 log-scale (Love et al., 2014) . Limma voom and DESeq2 were used to call differential expression 833 with either Positive cases vs Negative, or viral load (High/Medium/Low/None excluding any 834 samples with evidence of other viral infections) as reported by either qRT-PCR cycle threshold 835 (Ct) values, or using the inverted normalized Ct value as continuous response for viral levels, 836

where Ct of 15 is 1.0 and Ct of >40 is taken as 0 (Law et al., 2014) . Genes with BH-adjusted p-837 value < 0.01 and absolute log2 fold-change greater than 0.58 (at least 50% change in either 838 direction) were taken as significantly differentially regulated (Benjamini and Hochberg, 1995) . 839

The same approaches were repeated correcting for potential confounders in our data in two ways. 840

In the first correction ciliated cell fraction (as predicted by MUSIC) was added as another 841 covariate to our model. For the second correction SVA was run on the data and the resulting two 842 surrogate variables were included in a multivariate model (Leek et al., 2012) . The complete gene 843 list for all comparisons are given in Supp Table  849 3 . We defined a cohort of ACEI/ARB exposed patients as those that have 871

an ACEI/ARB prescription order sometime after January 1st, 2019. We compared the frequency 872 of ACEI/ARB exposure in three cohort comparisons: 873

i. SARS-CoV-2 tested positive patients versus SARS-CoV-2 tested negative patients, 874

ii. SARS-CoV-2 positive patients who require mechanical ventilation versus those who 875 did not, and 876

iii. SARS-CoV-2 positive patient survival versus death. 877

In addition, we perform one post-hoc comparison to evaluate the individual effects of particular 878

ACEIs or ARBs among SARS-CoV-2 positive patients who are exposed. 879 880

Cohort and Data Source 881

Our cohort data for SARS-CoV-2 suspected patients is extracted from the electronic health 882 records at NYPH-CUIMC. We used data collected starting on March 10th, 2020 through April 883 20th, 2020. In addition, we used data from 90,989 patients, who were not tested for SARS-CoV-884 2 infection and were 18 years or older, with available electronic health records from January 1st, 885 2019 through September 24th, 2019 to represent a comparison population of patients. In both 886

cases, data extracted included disease diagnoses, laboratory measurements, medication and 887 pharmacy orders, and patient demographics. We derived mortality from a death note filed by a 888 resident or primary provider that records the date and time of death. Intubation was used as an 889

intermediary endpoint and is a proxy for a patient requiring mechanical respiration. We used 890 note types that were developed for patients with SARS-CoV-2 infection to record that this 891 procedure was completed. We validated outcome data derived from notes against the patient's 892 medical record using manual review. 893 894

Experimental Statistical Methods 895

We conducted univariate analysis of the frequency differences of ACEI/ARB exposure and 896 multivariate regression analysis to account for established risk factors for SARS-CoV-2 897 outcomes (i.e. age, sex, baseline IL-6 upon admission, and comorbidities) (Zhou et al., 2020) . 898 We use logistic regression for analysis for comparing cohort (i) and performed survival analysis 899 using a Cox proportional hazards model for cohort comparisons (ii) and (iii Risk factors were assigned using OMOP CDM concept IDs 316866 for "Hypertensive Disorder", 911 317576 for "Coronary Arteriosclerosis", 201820 for "Diabetes mellitus", and 437525 for 912 "Overweight". In each case, the concept ID and all descendant concepts were used to define the 913 risk factor phenotype, and individuals were assigned the phenotype if they were assigned any of 914 the codes. 915 916

Statistical and visualization software 917

All electronic health data analyses were performed in Python 3.7 and all models were fit using R 918 3.6.3. Survival analyses (Cox regressions and survival curves) were performed with the survival 919 package for R, version 3.1-12. Additional statistical analyses, processing, transformation, and 920 The test samples were prepared using an optimized LAMP protocol from NEB, with a reaction time of 30 minutes. (c) Reaction progress was measured for the Twist SARS-CoV-2 synthetic RNA (MT007544.1) from 1 million molecules of virus (10 6 ), then titrated down by log10 dilutions. The colorimetric findings of the LAMP assay are based on a yellow to pink gradient with higher copies of SARS-CoV-2 RNA corresponding to a yellow color. The limit of detection (LoD) range is shown with a gradient after 30 minutes between 10 and 100 viral copies (lower right). (d) Replicates of the titrated viral copies using LAMP, as measured by QuantiFluor fluorescence. (e) The sensitivity and specificity of the LAMP assay from 201 patients (132 negative and 69 positive for SARS-CoV-2, as measured by qRT-PCR). Thresholds are DNA quantified by the QuantiFluor. (left) and the global map of known SARS-CoV-2 genomes (right). Genetic variants called from the RNA-seq data (middle) show a range of variants that are distinct from the Wuhan reference strain, and the samples from this study, highlighted in blue, show enrichment for European and Asian alleles. The annotation track on the bottom shows variants called in these samples alongside all other GISAID samples. Samples that diverge from GISAID by more than 5% in either direction are annotated, including their coordinate and substitution event. (b) Proportion of the L (green) and S strain (yellow) are shown for the NYC viruses. Phylogeny of samples from this study on the left and total GISAID samples on the right, with a map of variants in this study's samples in the middle, colored by event type and sized by number of nucleotides impacted. Annotation track on the bottom shows frequency of alternate alleles in this study and in the GISAID database. (c) The 9-bp deletion in ORF1b (NSP1 protein) that was detected in samples from three NYPH-WCMC patients was confirmed in the GISAID database (bottom tracks). Read-level support is shown in the top tracks for two of the variants, with aligned contigs visualized below. Assembly alignments for 17 additional cases harboring this deletion, including 1 additional case from this study are shown in the bottom track. (d) Alignment of SARS-CoV-2 to SARS-CoV NSP1 protein sequence is shown, with an enlarged view showing a sequence similarity track (normalized protein alignment score in 5 amino acid sliding window) and the 9-bp deletion region delineated. (top row) Samples were quantified by a range of viral load, including RNA-seq (log10 SARS-CoV-2 % of reads), and qRT-PCR (Ct values) to create a three-tier range of viral load for the positive samples (right) compared to the clinically-annotated negative samples (class, red or grey) and those samples with other viral infections that were SARS-CoV-2 negative by qRT-PCR. (b) The differentially expressed genes of qRT-PCR positive patients compared to qRT-PCR patients showed up-regulated (orange) genes as well as downregulated (purple) genes. (b) Up-regulated genes, with boxplots across all samples, include IFI6, ACE2, SHFL, HERC6, IFI27, and IFIT1, based on data from (c), which is the total set of DEGs. The full set is shown in an intersecting heat map, with a core set of up-regulated genes (orange) distinct form the set of down-regulated genes (purple), compared to genes that are not significantly differently expressed (grey) in any comparison (DESeq2, q-value <0.01, |logFC| >0.58). (d) GSEA enrichment of significant pathways, with color indicating statistical significance and circle size the number of genes on the leading edge (e) Regression coefficients for variables indicating exposure/history of exposure to ACEI/ARBs inhibitors for each of the three cohort comparisons: (left) test outcome in a cohort of patients suspected of SARS-CoV-2 infection, (middle) requirement of mechanical respiration in patients who tested positive, (right) mortality in patients who tested positive. Univariate analyses are shown as red circles. The green triangles coefficients are when correcting for age, sex, and baseline IL-6 levels take upon admission. The blue squares are from a model that includes age, sex, and IL-6 as well as comorbidities including CAD/CHD, diabetes, being overweight, or obesity, and self-reported race and ethnicity. Additionally, open markers indicate the same analyses but restricted to only patients with clinically diagnosed hypertension. (f) Curves for patients requiring mechanical respiration (identified by intubation procedure notes) as a function of drug class (g) and survival, conditioned on hypertension status and ACEI/ARB exposure status. 

Supplemental Figure 1 . LAMP Primer Design. PrimerDesigner (v4) was used to create a set of six primers that would specifically target the nucleocapsid gene (N) in the SARS-CoV-2 genome. Primer sequences are listed in the methods section.

Samples were prepared using the LAMP protocol with a reaction time of 30 minutes. Reaction progress was measured (a) from 0, 20, and 30 minutes. (b) This was repeated for both Twist SARS-CoV-2 synthetic RNAs (MT007544.1, top and MN908947.3, middle) from 1 million molecules of virus (10 6 ), then titrated down by log10 dilutions. Limit of Detection (LOD) range is shown with a gradient after 30 minutes between 10 and 100 viral copies. (bottom) A clinically positive sample that was not detectible by Qubit (<0.05 ng/mL) was nonetheless detected by LAMP, in accordance with detection of low viral titer samples. Supplemental Figure 3 . Reproducibility, sensitivity, and specificity for the LAMP Assay. (a) Testing with a synthetic SARS-CoV-2 RNA that was serially titrated and measured in replicates (n=10) showed 100% and 95% reproducibility at 1,000 and 500 copies, respectively, with lower rates at lower viral titers. (b) Replicates of a clinically positive (by qRT-PCR) sample at 10 uL (blue) compared to 5uL (green) showed high concordance, with greater sensitivity with increased reaction volume. (c) Whole oropharyngeal swab lysates from clinical positive (Cp-value >0) and negative samples (Cp = NA) were used to test the LAMP reaction. (d) The standard curve with synthetic RNA was also tested relative to absolute number of copies (x-axis) and the Cp value (y-axis). (e) The Cp value for the LAMP positive (+, right) and negative (-, left) were compared to the Cp value from qRT-PCR (y-axis).

With increasing viral load, as measured by qRT-PCR, the LAMP assay shows an increased sensitivity (y-axis) and specificity (y-axis). For high and medium viral count samples (Ct < 28, red and green line), we see 100% sensitivity, and for low viral count, we see 81% sensitivity and 100% specificity (blue). Across all data (purple), we see 95.6% sensitivity and 99.4% specificity. RFU thresholds are shown as numbers. 

Biostrings') and additional Imielinski Lab R packages ('gTrack', 'gChain', 922 'gUtils

Olmesartan Is an Angiotensin II Receptor Blocker with an Inhibitory Effect on Angiotensin-929 Converting Enzyme

Biosynthesis of heme in mammals

A serological assay to detect SARS-CoV-2 937 seroconversion in humans

Quality Control tool for High Throughput Sequence Data

Controlling the False Discovery Rate: A Practical and Powerful 944 Approach to Multiple Testing

Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPR-based 949 DETECTR Lateral Flow Assay

MView: A Web compatible database search or 953 multiple alignment viewer

Manta: rapid detection of structural variants and indels for germline and cancer 957 sequencing applications

Ultra-fast personal genome analysis and interpretation

Global Genetic Cartography of Urban 964 Metagenomes and Anti-Microbrial Resistance 965

Metagenomic sequencing 968 with spiked primer enrichment for viral diagnostics and genomic surveillance

An interactive web-based dashboard to track COVID-19 in real time

disease and diplomacy: GISAID's innovative contribution to 975 global health

Summarize analysis results for multiple 978 tools and samples in a single report

nf-core: Community curated bioinformatics pipelines

Scalable small variant 984 calling across heterogeneous next-generation sequencing experiments

Are patients with hypertension and diabetes mellitus at 988 increased risk for COVID-19 infection?

Coast-to-coast spread of SARS-CoV-2 during the early epidemic in the United 991 States

Real-time digital pathogen surveillance -the time is now

Introductions and early spread of SARS-CoV-2 1001 in the New York City area

Clinical Characteristics of Coronavirus Disease 2019 in China. NEJM

CoV-2 variant calling and consensus assembly pipeline

An amplicon-based sequencing framework for accurately measuring 1014 intrahost virus diversity using PrimalSeq and iVar

Nextstrain: Real-Time Tracking of Pathogen Evolution

Coronavirus Disease 2019 (COVID-19): What we know

SARS-CoV-2 Cell Entry Depends on 1025 ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Transient structural variations have strong effects on 1029 quantitative traits and reproductive isolation in fission yeast

In silico approach to accelerate the development of mass 1033 spectrometry-based proteomics methods for detection of viral proteins: Application to COVID-1034 19

Adjusting batch effects in microarray expression data using 1037 empirical Bayes methods

MAFFT multiple sequence alignment software version 7: Improvements 1040 in performance and usability

Rapid Establishment of Laboratory Diagnostics for the Novel Coronavirus SARS-CoV-2 1045 in Bavaria

The architecture of SARS-CoV-2 1048 transcriptome

Enrichr: a comprehensive gene set enrichment analysis web server 2016 1051 update

Positive RT-PCR Test Results in Patients 1054 Recovered from COVID-19

Fast Gapped-Read Alignment with Bowtie 2

The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported 1061 Confirmed Cases: Estimation and Application

Voom: Precision weights unlock linear model 1065 analysis tools for RNA-seq read counts

LUMPY: a probabilistic framework for structural 1068 variant discovery

The SVA package for 1071 removing batch effects and other unwanted variation in high

A statistical framework for SNP calling, mutation discovery, association mapping and 1075 population genetical parameter estimation from sequencing data

Toolkit for processing sequences in FASTA/Q formats

Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM

The Sequence Alignment/Map format and SAMtools

Substantial undocumented infection 1086 facilitates the rapid dissemination of novel coronavirus (SARS-CoV2)

Molecular signatures database (MSigDB) 3.0. Bioinformatics

Positive Rate of RT-PCR Detection of 1091 SARS-COV-2 Infection of 4880 Cases from One Hospital

SARS-CoV-2 is 1095 sensitive to type 1 interferon pretreatment

Moderated estimation of fold change and dispersion for RNA-seq data with 1099 DESeq2

Genomic epidemiology of SARS-CoV-2 in Guangdong Province, China

SARS-CoV-2 receptor ACE 2 and TMPRSS 2 are primarily expressed in 1104 bronchial transient secretory cells

Analysis of the fecal microbiota of irritable bowel syndrome patients and 1107 healthy controls with real-time PCR

CRISPR-based 1110 surveillance for COVID-19 using genomically-comprehensive machine learning design

Selvarangan 1116 R. Enterovirus D68 Outbreak Detection Through A Syndromic Disease Epidemiology Network

Inhibition of 1122 SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble 1123 Human ACE2

A cloud-compatible bioinformatics pipeline for ultrarapid pathogen 1126 identification from next-generation sequencing of clinical samples

Coronavirus nonstructural 1129 protein 1: Common and distinct functions in the regulation of host and viral gene 1130 expression

Advanced multi-sample quality 1133 control for high-throughput sequencing data

Surface 1136 Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory 1137 Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient

Versteeg 1143 GA. HERC6 is the main E3 ligase for global ISG15 conjugation in mouse cells

COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin 1147 Receptor Blockers. What is the evidence?

Performance of rapid influenza diagnostic 1150 testing in outbreak settings

StringTie enables improved reconstruction of a transcriptome from RNA-seq 1153 reads

Effectiveness of airport screening at detecting 1156 travellers infected with 2019-nCoV

A scaling normalization method for differential expression analysis of 1160 RNA-seq data

DELLY: structural variant 1163 discovery by integrated paired-end and split-read analysis

Integrative Genomics Viewer

Type 2 and interferon inflammation strongly 1171 regulate SARS-CoV-2 related gene expression in the airway epithelium

TreeTime: Maximum-likelihood phylodynamic analysis

dupRadar: A Bioconductor package for the assessment of 1178 PCR artifacts in RNA-Seq data

An algorithm for fast preranked gene set enrichment analysis using cumulative 1181 statistic calculation

Transmission Potential of SARS-CoV-2 in Viral Shedding Observed at the University of 1186 Nebraska Medical Center

Population-Scale COVID-19 Diagnostics Using a Compressed 1191 Barcode Space

BBMap short-read aligner, and other bioinformatics tools

Global initiative on sharing all influenza data -from vision to 1200 reality

2018: 1208 Knowledgebase for the laboratory mouse

Gene set enrichment analysis: A knowledge-based approach for 1211 interpreting genome-wide expression profiles

SARS-CoV-2 enry factors are highly 1214 expressed in nasal epithelial cells together with innate immune genes

Direct RNA sequencing and early 1218 evolution 2 of SARS-CoV-2

1222 On the origin and continuing evolution of SARS-CoV-2, National Science Review

Visual Detection of Isothermal Nucleic Acid Amplification 1225 Using pH-Sensitive Dyes

Transmembrane Protease 1229 TMPRSS11B Promotes Lung Cancer Growth by Enhancing Lactate Export and Glycolytic 1230 Metabolism

Aerosol and surface 1234 stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1. 2020

A cellular census of human lungs identifies novel cell states in health 1238 and in asthma

Quality control of RNA-seq experiments

Bulk tissue cell type deconvolution with 1244 multi-subject single-cell expression reference

Virological assessment of hospitalized cases of 1250 coronavirus disease 2019

Improved metagenomic analysis with Kraken 2

Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal 1258 swabs

Using ggtree to visualize data on tree-like structures

Rapid Colorimetric Detection of COVID-19 Coronavirus Using a Reverse 1265 Transcriptional Loop-Mediated Isothermal Amplification (RT-LAMP) Diagnostic Platform: 1266 iLACO

Mycobacterium avium subsp. paratuberculosis and associated risk factors for 1270 inflammatory bowel disease in Iranian patients

Characterizing geographical and temporal dynamics of novel 1273 coronavirus SARS-CoV-2 using informative subytype markers

Association of Inpatient Use of Angiotensin 1277 Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among 1278 Patients With Hypertension Hospitalized With COVID-19

Rapid Molecular 1281 Detection of SARS-CoV-2 (COVID-19) Virus RNA Using Colorimetric LAMP

Clinical course and risk factors for mortality of 1286 adult inpatients with COVID-19 in Wuhan

Phylogenetic tree produced by the Nextstrain analysis with clade affiliations and nodes corresponding to WCM/NYP in red and other NYC cases in green. (right) occurrence of the six NYC-enriched alleles and the 9 nucleotide deletion across genomes. (c) Raw counts of cases present within this A2-25563 subclade demonstrated a predominance of European and North American cases, with Western Europe and New York together comprising the majority of strains. (d) Fraction of A2-25563 cases from each region of the world

ACEI and ARB 163 (<0.1%) (69.9-87) Male

) 95 (18%) Caucasian 108 (0.1%) 2587 (29.2%) 1249 (25.9%) 127 (23.8%) 141 (26.7%) Asian or Pacific

) 151 (28.3%) 58.9%)

.2%) 831 (9.4%) 511 (10.6%) 92 (17.2%) 137 (25.9%) Diabetes

20200316-P1 1-F08-N COV-20200316-P1 1-D08-N COV-20200316-P1 1-G06-N COV-20200316-P1 1-F05-N COV-20200316-P1 2-H08-N COV-20200316-P1 2-F09-N COV-20200316-P1 2-F05-N COV-20200316-P1 2-D05-N COV-20200316-P1 2-D07-N COV-20200316-P1 2-E07-N COV-20200316-P1 2-G07-N COV-20200316-P1 2-E05-N COV-20200316-P1 2-H04-N COV-20200316-P1 2-E04-N COV-20200316-P1 2-F06-N COV-20200316-P1 2-F04-N COV-20200316-P1 2-H06-N COV-20200316-P1 2-G05-N COV-20200316-P1 2-C05-N COV-20200316-P1 2-H07-N COV-20200316-P1 2-A0 2-P COV-20200316-P1 2-A0 9-P COV-20200316

Saline) Pos Cntl #2 (Saline) Pos Cntl #1 (Water Pos Cntl #2 (Water)

to create a three-tier range of viral load for the positive samples (right) compared to the clinically-annotated negative samples (class, red or grey). (bottom) The differentially expressed genes of SARS-CoV-2 positive patients compared to SARS-CoV-2 negative patients showed up-regulated (orange) genes as well as down-regulated (purple) genes. All differentially expressed genes with adjusted p-value < 0.001 and |log2 fold-change| > 1.5 (> 2.82 fold) are shown across different patient groups by viral level and presence of other viral pathogens. (b) Intersection heatmap of differentially expressed genes across different comparisons with genes in x-axis and comparisons in y-axis, with a core set of upregulated genes (orange) distinct form the set of down-regulated genes (purple), compared to genes that are not significantly differently expressed (grey) in any comparison (Limma voom, q-value <0.01, |log2FC| >0.58).Supplemental Figure 13 . ACEI/ARBs Multivariate and Comparative Analyses. Comparison of the effects of different ACEIs (benazepril, enalapril, lisinopril, ramipril) and ARBs (losartan, olmesartan, telmisartan, valsartan) when compared to patients exposed to other ACEIs or ARBs, respectively. There were no significant findings amongst the different ACEIs. However, among the ARBs we found that olmesartan was associated with a significant increase in mortality (HR=2.3 CI: 1.1-4.9, p=3.05E-02). 

Supplemental Table 4 . Gene Ontology Pathways. Appended.

Appended.

Appended.

Appended.

Appended.

Appended.

Appended.